Understanding our core competence of developing best quality generic medicines at the most affordable cost, MSN Laboratories' investment in research and development (R&D) began in 2003. As an attempt to minimize the project management time lines, it was necessary to have R&D activities of both API and formulation under one roof. The vision of the founder took shape as a fully integrated R&D facility in 2012.
The very foundation of MSN Laboratories and all its ventures is our Research and Development center.
In the sprawling 750,000 sq. ft. facility, our scientists are relentlessly working on all facets of pharmaceutical development and technology. Formulation and method development, stability supervision, trial materials and commercial production - the R&D center does not compromise on quality when it comes to on-time delivery. Apart from developing new products R&D is also involved in product life cycle management activities to ensure continuous quality improvements. With an outstanding workforce, a state-of-the-art technology base and knowledge intensive initiatives, we take on speedy, innovative solutions for providing affordable healthcare solutions.
Our endless research is focused on developing new products, improving existing ones, refining drug delivery systems and expanding product applications. With 42 labs and more than 1100 scientists in our team, we have achieved 17 First in the world generics and 650 patents till date. We have been able to achieve synergistic integration between API and FDF. At present, our growing portfolio consists of 567 DMFs, 2000 dossiers and 40 ANDAs registered. Pioneers in developing complex products, our reach is now global - not just in markets, but we also have offices in New Jersey - USA, Brazil, Chile, Nairobi, Vietnam and a few other international locations.